Vancomycin-resistente enterokokken: Welche therapieoptionen gibt es?

Translated title of the contribution: Treatment options for serious infections caused by vancomycin-resistant enterococci

Nico T. Mutters, Guido Werner, Evelina Tacconelli, Alexander Mischnik*

*Corresponding author for this work
5 Citations (Scopus)

Abstract

Abstract Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.

Translated title of the contributionTreatment options for serious infections caused by vancomycin-resistant enterococci
Original languageGerman
JournalDeutsche Medizinische Wochenschrift
Volume140
Issue number1
Pages (from-to)42-45
Number of pages4
ISSN0012-0472
DOIs
Publication statusPublished - 12.01.2015

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'Treatment options for serious infections caused by vancomycin-resistant enterococci: Welche therapieoptionen gibt es?'. Together they form a unique fingerprint.

Cite this